Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 27, 2026.

Sign in

Summit Therapeutics Inc.

SMMT Nasdaq Pharmaceutical Preparations Financials FY2018–FY2025

Add to portfolio Download report
Today
6.3%
Previous close
$15.47
Market cap
$11.3B
P/E
β€”
52-week range
$12.43 $26.38

Last close Β· Oct 26, 2026

$14.50

βˆ’$4.78 (βˆ’24.79%) past year

Share price

Summit Therapeutics Inc.

What Summit Therapeutics Inc. does

SMMT Β· Pharmaceutical Preparations

From its latest annual report

No business description yet.

Filing details

Legal name
Summit Therapeutics Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Feb 23, 2026
Accession Β· CIK
0001599298-26-000015 Β· 0001599298

Earnings calendar Β· Summit Therapeutics Inc.

Every quarter, companies publish how much they sold and earned. These are the days Summit Therapeutics Inc. did it, and the next one. Share prices often move a lot on those days.

Next results

October 26, 2026

Monday Β· expected, not published yet

Time
Time not announced
Covers
Period ended Sep 30, 2026
Expected EPS
βˆ’$0.28
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Oct 26, 2026 Period ended Sep 30, 2026 Time not announced Earnings calendar
Jul 23, 2026 Q2 '26 After the market closes 8-K β†—
Apr 30, 2026 Q1 '26 After the market closes 8-K β†—
Jan 12, 2026 Q4 '25 Before the market opens 8-K β†—
Oct 17, 2025 Q3 '25 Time not announced 8-K β†—
Aug 11, 2025 Q2 '25 After the market closes 8-K β†—
May 1, 2025 Q1 '25 After the market closes 8-K β†—
Jan 13, 2025 Q4 '24 Before the market opens 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Summit Therapeutics Inc.’s latest annual report (fiscal 2025). Here is what stands out:

2 to watch

Summit Therapeutics Inc. in 30 seconds

Good So-so Weak

Weak

Does it make a profit?

βˆ’$1.1B

No. It lost money last year.

For information

How is the share priced?

β€”

No P/E: it made no profit over the last four quarters.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$11.3B
Oct 26 close
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$1.11 EPS (TTM)

Revenue

Total sales reported in the income statement.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Summit Therapeutics Inc. lost $1.1B in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was βˆ’$324M in fiscal 2025, β€” of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

Revenue

Revenue

Margins, % of revenue

Gross Operating Net FCF

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Net income and earnings per share

Loss periods are shown in red.

KIRA summarises the numbers

  • Summit Therapeutics Inc. lost $1.1B in fiscal 2025.

Net income

Net income

Diluted EPS

Diluted EPS

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

Cash from operations minus capital spending.

KIRA summarises the numbers

  • Free cash flow was βˆ’$324M in fiscal 2025, β€” of revenue.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Dividends, buybacks and share count

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

KIRA summarises the numbers

  • In the last 12 months, insiders bought $104M of shares on the open market and sold none.

Bought, 12 months

$104M

3 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

β€”

$0.0M

DateInsiderTradeSharesPriceValueFiling
Jun 12, 2026 Mahkam ZanganehCo-Chief Executive Officer, Director, 10% owner Bought 3,810,000 $13.12 $50.0M Form 4
Jun 12, 2026 Robert W DugganCo-Chief Executive Officer, Director, 10% owner Bought 3,810,000 $13.12 $50.0M Form 4
Jun 4, 2026 Mahkam ZanganehCo-Chief Executive Officer, Director, 10% owner Bought 100,000 $14.60 $1.5M Form 4
Jun 4, 2026 Manmeet Singh SoniCOO and CFO, Director Bought 50,000 $14.45 $0.7M Form 4
Jun 4, 2026 Robert W DugganCo-Chief Executive Officer, Director, 10% owner Bought 100,000 $14.60 $1.5M Form 4
Oct 21, 2025 Robert W DugganCo-Chief Executive Officer, Director, 10% owner Bought 26,680 $18.74 $0.5M Form 4
Oct 21, 2025 Yu XiaDirector Bought 533,617 $18.74 $10.0M Form 4

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably Summit Therapeutics Inc. can carry it.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $71.8M$349M$186M$412M$713M
Interest coverage βˆ’356.1xβˆ’16.4xβˆ’37.0xβˆ’26.0xβ€”
Current ratio 3.8x16.9x9.3x10.2x9.9x
Quick ratio 3.8x16.9x9.3x10.2x9.9x
Total assets $113M$664M$203M$436M$751M
Total liabilities $30.1M$538M$125M$46.8M$92.3M
Shareholders' equity $83.3M$127M$77.7M$389M$659M
Net debt (βˆ’ = net cash) β€”β€”β€”β€”β€”

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY18FY21FY22FY23FY24FY25
Net income is positive βœ“ βœ• βœ• βœ• βœ• βœ•
Cash from operations is positive βœ• βœ• βœ• βœ• βœ• βœ•
Return on assets rose β€” β€” βœ“ βœ• βœ“ βœ•
Cash from operations exceeds net income βœ• βœ“ βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” β€” β€” β€” β€” β€”
Current ratio rose β€” βœ• βœ“ βœ• βœ“ βœ•
Share count didn't rise β€” β€” βœ• βœ• βœ• βœ•
Gross margin rose β€” β€” β€” β€” β€” β€”
Revenue rose relative to assets β€” β€” βœ• βœ• βœ• β€”
F-score β€” / 3β€” / 43 / 71 / 73 / 7β€” / 6
Accruals ratio β€”βˆ’14.8%βˆ’9.6%βˆ’124.1%βˆ’24.8%βˆ’127.5%
Altman Z'' β€”βˆ’6.673.76βˆ’30.021.90β€”

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

All figures

Every number, year by year.

7 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

Download CSV
Fiscal yearFY18FY20FY21FY22FY23FY24FY25
Income statement
Revenue $57.1M β€” $1.8M $0.7M $0.0M $0.0M β€”
Research and development $52.0M β€” $85.4M $52.0M $59.5M $151M $538M
Operating income $5.4M β€” βˆ’$86.2M βˆ’$72.1M βˆ’$610M βˆ’$226M β€”
Interest expense $0.6M β€” $0.2M $4.4M $16.5M $8.7M $0.0M
Pretax income $9.1M β€” βˆ’$88.6M βˆ’$78.8M βˆ’$615M βˆ’$221M βˆ’$1.1B
Income tax βˆ’$1.8M β€” $0.0M β€” $0.0M $0.0M $0.0M
Net income $10.9M β€” βˆ’$88.6M βˆ’$78.8M βˆ’$615M βˆ’$221M βˆ’$1.1B
Diluted EPS $0.63 β€” βˆ’$0.67 βˆ’$0.41 βˆ’$0.99 βˆ’$0.31 βˆ’$1.44
Diluted shares 0.02B β€” 0.13B 0.19B 0.62B 0.72B 0.75B
Cash flow
Cash from operations βˆ’$35.1M β€” βˆ’$72.6M βˆ’$41.6M βˆ’$76.8M βˆ’$142M βˆ’$323M
Capital expenditure $0.2M β€” $0.3M $0.6M $0.1M $0.1M $0.7M
Free cash flow βˆ’$35.3M β€” βˆ’$72.9M βˆ’$42.2M βˆ’$76.9M βˆ’$142M βˆ’$324M
Depreciation and amortization $0.4M β€” $0.3M $0.3M $0.2M $0.1M $0.1M
Stock-based compensation $6.3M β€” $12.8M $11.9M $14.1M $51.0M $732M
Dividends paid $0.0M β€” β€” β€” β€” β€” β€”
Dividends and buybacks $0.0M β€” β€” β€” β€” β€” β€”
Balance sheet
Cash and short-term investments $35.2M $66.4M $71.8M $349M $186M $412M $713M
Current assets β€” $87.7M $97.3M $657M $190M $424M $720M
Current liabilities β€” $19.9M $25.6M $38.8M $20.4M $41.7M $73.0M
Property and equipment, net β€” $0.7M $0.7M $0.9M $0.2M $0.3M $1.1M
Goodwill $2.0M $2.0M $2.0M $1.8M $1.9M $1.9M $2.0M
Intangible assets β€” $11.5M $10.4M $0.0M $0.0M $0.0M β€”
Total assets β€” $102M $113M $664M $203M $436M $751M
Total liabilities β€” $23.0M $30.1M $538M $125M $46.8M $92.3M
Preferred stock β€” β€” $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity $57.6M $79.5M $83.3M $127M $77.7M $389M $659M
Margins
Operating margin 9.4% β€” βˆ’4,764.3% βˆ’10,225.4% β€” β€” β€”
EBITDA margin 10.2% β€” βˆ’4,746.0% βˆ’10,175.9% β€” β€” β€”
Net margin 19.0% β€” βˆ’4,897.8% βˆ’11,174.8% β€” β€” β€”
FCF margin βˆ’61.8% β€” βˆ’4,029.5% βˆ’5,986.7% β€” β€” β€”
Returns
Return on capital employed β€” β€” βˆ’98.2% βˆ’11.5% βˆ’334.0% βˆ’57.4% β€”
Return on equity 18.9% β€” βˆ’108.9% βˆ’75.1% βˆ’601.8% βˆ’94.9% βˆ’206.1%
Return on assets β€” β€” βˆ’82.1% βˆ’20.3% βˆ’141.8% βˆ’69.3% βˆ’181.9%
Return on tangible equity 19.5% β€” βˆ’125.0% βˆ’63.1% βˆ’811.3% βˆ’57.2% βˆ’164.4%
Growth
Revenue growth β€” β€” β€” βˆ’61.0% βˆ’100.0% β€” β€”
Share count change β€” β€” β€” 46.8% 220.5% 16.0% 4.1%
Financial health
Interest coverage 8.7x β€” βˆ’356.1x βˆ’16.4x βˆ’37.0x βˆ’26.0x β€”
Current ratio β€” 4.4x 3.8x 16.9x 9.3x 10.2x 9.9x
Quick ratio β€” 4.4x 3.8x 16.9x 9.3x 10.2x 9.9x
Capital allocation
Capex / revenue 0.3% β€” 16.9% 88.5% β€” β€” β€”
Stock comp / revenue 11.0% β€” 707.8% 1,694.8% β€” β€” β€”
Quality scores
Piotroski F-score β€” β€” β€” 3.0 1.0 3.0 β€”
Altman Z'' β€” β€” βˆ’6.7 3.8 βˆ’30.0 1.9 β€”
Accruals ratio β€” β€” βˆ’14.8% βˆ’9.6% βˆ’124.1% βˆ’24.8% βˆ’127.5%

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Source: SEC EDGAR XBRL filings (CIK 0001599298). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open